The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Purifloh (PO3) Chairman Bill Parfet has announced his resignation from the head position and as the company’s Director of the Board
  • The former Chairman announced the news this morning, stating the resignation was effective immediately
  • Bill has thanked the company for the opportunity but is focused on spending more time with his family in retirement
  • Purifloh Director Carl Le Souef will step into the Chairman role on an interim basis
  • Shares in Purifloh have opened trading down 21.1 per cent for $1.50

Purifloh (PO3) Chairman, Bill Parfet, has announced his resignation from the Chairman position and stepped down as the Director of the Board.

In a statement, Bill thanked the company for the opportunity and said he had decided to spend more time with his family in retirement.

“It has been an honour to lead Purifloh over the past 12 months though I now wish to spend more time in retirement with my family,” he said.

“I depart with nothing but good wishes and best regards for the company, my fellow Board Members and the management team,” he added.

The former Chairman will retain his shareholding in Purifloh and has offered his continued support to the company.

Bill will be replaced by current Purifloh Director Carl Le Souef, who will step into the Chairman role on an interim basis.

Carl also controls the company’s major shareholder, the business Dilato Holdings.

“All shareholders owe a debt of gratitude towards Bill for his investment in Purifloh, together with his efforts on behalf of the company,” the new interim Chairman said.

“We thank Bill for his support and leadership and wish him the very best in his retirement,” he added.

The director also promised to release another update on Purifloh’s activities soon, with the company announcing its annual report yesterday.

The company, which creates technology for purifying air, water and surfaces, announced the leadership news before market open on Friday.

Shares in the company have since dropped as investors react, trading down 21.1 per cent, with shares worth $1.50 at 10:38 am AEST.

PO3 by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…